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a  b  s  t  r  a  c  t
Background:  In the emergent  setting  of  ST-elevation  myocardial  infarction  (STEMI),  transradial  inter-
vention  (TRI)  is less  frequently  employed  than  transfemoral  intervention  (TFI). Because  of  the  greater
technical  complexity  of  TRI,  a potential  compromise  in  door-to-balloon  (DTB)  time remains  a major
concern  of centers  adopting  TRI for  STEMI.
Methods:  We  performed  a propensity-matched  analysis,  with  1:1  matching  of  TRI  and  TFI patients  com-
paring  DTB  time,  30-day  major  adverse  cardiac  event  (MACE),  and  bleeding  outcomes  of  1052 consecutive
STEMI  patients  managed  at our center  during  a 2-year  transition  program  from  routine  TFI  to TRI  access
for STEMI.
Results:  From  January  2008  to April  2010,  359  (34.1%)  STEMI  patients  underwent  TRI and the  remaining
693  (65.9%)  STEMI  patients  underwent  TFI. In 283  propensity  score  matched  pairs  of  TRI and  TFI patients,
TRI  was  associated  with  shorter  DTB  time  (63.6  min  vs  69.4 min,  p =  0.027)  and  more  patients  having  DTB
time  < 90  min  (88.3%  vs  82.3%,  p = 0.043).  Thirty-day  MACE  occurred  in  1.0%  in  the  TRI  group  and  3.0%
in  the TFI  group  (p =  0.129).  There  was  no  signiﬁcant  difference  in  major  (p = 0.313)  or minor  bleeding
(p  =  0.714)  between  the  TRI  and  TFI  groups.  There  was  a twofold  greater  use  of  glycoprotein  (GP)  IIb/IIIa
inhibitor  in the TRI group  (68.5%)  compared  with  the TFI group  (36.4%)  (p <  0.001).
Conclusion:  Compared  with  TFI,  TRI  was  not associated  with  longer  DTB  time  during  our center’s  transition
from  routine  TFI to TRI in STEMI.  Our experience  suggests  that  the  transition  to  TRI  in STEMI  can  be safely
 that  
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Transradial intervention (TRI) is increasingly becoming the pre-
erred method of vascular access at many centers performing
ercutaneous coronary intervention (PCI). Compared with trans-
emoral intervention (TFI), perceived beneﬁts of TRI include lower
ccess site bleeding and greater patient comfort. Several stud-
es have now shown signiﬁcant reductions in bleeding and even
schemic complications with TRI in ST-elevation myocardial infarc-
ion (STEMI) [1–7].
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Aggressive anti-thrombotic therapy is a cornerstone of primary
PCI in order to limit the occurrence of thrombotic complications
during and after the procedure. Hachinohe et al. reported that use
of glycoprotein (GP) IIb/IIIa inhibitor with thrombus aspiration has
a synergistic effect on clinical outcomes for patients with acute
myocardial infarction [8]. Therefore, bleeding is one of the main
concerns for operators. The radial artery is easily compressible, thus
bleeding is controllable and hemorrhagic complications can be sig-
niﬁcantly reduced. Furthermore, TRI is associated with lower access
site bleeding compared with TFI [1–4]; thus, a theoretical advan-
tage of TRI over TFI is that more potent anti-thrombotic drugs can
be administered prior to, or during, primary PCI.There are concerns that a routine TRI approach may  result
in longer door-to-balloon (DTB) time compared with a routine
TFI approach, particularly with centers considering the adop-
tion of TRI in STEMI. In the emergent setting of STEMI where
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imely revascularization is paramount, technical concerns remain
bout radial artery access and negotiating tortuous subclavian and
scending aortic anatomy in patients with ongoing STEMI. We
herefore sought to compare differences in DTB time, bleeding,
nd thrombotic outcomes among patients undergoing TRI and TFI




We  conducted an observational study of 1052 Asian patients
ith STEMI undergoing primary PCI at a high-volume tertiary med-
cal center in Singapore from January 2008 to April 2010. We
ncluded all patients who presented to the emergency department
ith STEMI and were eligible for primary PCI. All patients received
 loading dose of aspirin 300 mg  and clopidogrel 600 mg  on arrival
n the emergency department. Periprocedural use of GP IIb/IIIa
nhibitors was determined by the primary operator in accordance
ith current guidelines [9]. Unfractionated heparin was  adminis-
ered at a bolus dose of 50–70 units/kg for all patients and adjusted
o achieve an activated clotting time of 250–300 s and 300–350 s,
espectively, for patients who did and did not receive GP IIb/IIIa
nhibitors.
Door-to-balloon time was deﬁned as time intervals between
atients’ arrival to the emergency department and the moment
f ﬁrst attempt to open the artery by thrombectomy, balloon
nsertion, or stenting. Major cardiac adverse events (MACE) of
nterest were death, myocardial infarction, and target vessel revas-
ularization that happened in the catheter laboratory, or within
0 days post-PCI follow-up that was done through telephone calls
nd clinic visits. The deﬁnition of major bleeding include the
umulative occurrence within 30 days after PCI of intracranial or
ntraocular bleeding, hemorrhage at the access site requiring inter-
ention, hematoma with a diameter of at least 5 cm,  a reduction
n hemoglobin levels of at least 4 g per deciliter without an overt
leeding source or at least 3 g per deciliter with such a source, re-
peration for bleeding, or transfusion of a blood product which
ere based on the ACUITY trial [10]. Minor bleeding was deﬁned as
ny bleeding that did not meet the above major bleeding criteria.
ollow-up information was obtained from the hospital records. The
rimary outcomes were DTB time, major and minor bleeding, and
ACE within 30 days after the index procedure.
tatistical analysis
Statistical analysis was performed using STATA (release 11.0;
tataCorp, College Station, TX, USA) statistical software. Cate-
orical variables will be presented as numbers and percentages
ith 95% conﬁdence interval (CI), and continuous variables, as
eans ± standard deviation (SD) or median and range, depend-
ng on the distribution of data. In this propensity score matched
nalysis, we compared the baseline covariates between the 2 inter-
ention groups, TRI and TFI. Continuous variables were compared
sing the t-test, and categorical variables were compared using
ither the chi-square test or Fisher’s exact test as appropriate. A
wo-sided p-value of less than 0.05 was considered statistically
igniﬁcant.
To investigate the treatment effect (i.e. radial approach vs
emoral approach) on the different clinical outcomes, such as
0-day MACE, major bleeding, minor bleeding, and longer DTB
ime >90 min, univariate and multivariate stepwise logistic regres-
ion analyses were applied. In the multivariate stepwise logistic
egression analysis procedure, variables with p ≤ 0.1 in the bivariateiology 62 (2013) 12–17 13
analysis were further considered for inclusion in the multiple logis-
tic regression model so as not to miss any potentially important pre-
dictors. To choose among competing models, the preferred logistic
regression model was selected based on the log-likelihood ratio.
The treatment effect on clinical end points was quantiﬁed using
the odds ratio (OR) estimate and its associated 95% CI.
To estimate the treatment effect on the continuous outcome of
DTB time, the generalized linear model (GLM) using Gaussian fam-
ily, identity link function, and main effect model was  exploited.
Further adjustment for potential confounders was  made in this
analysis. In addition, pair-wise comparisons for the mean values of
DTB times between 2 treatment groups and other signiﬁcant factor
variables were also estimated.
We also performed an additional analysis to conﬁrm the above
analysis based on adjusted treatment effects (i.e. adjusted for
signiﬁcant covariates) using the propensity score matched analy-
sis approach to provide unbiased estimation of treatment effect,
which usually occurred in the observational study because the
effectiveness of a treatment may  depend on some characteristics
that are associated with non-random assignment of treatment. In
this propensity score matched analysis, we compared the baseline
covariates between the 2 intervention groups. Continuous variables
were compared using the t-test, and categorical variables were
compared using either the chi-square test or Fisher’s exact test as
appropriate. A two-sided p-value of less than 0.05 was considered
statistically signiﬁcant.
Then, we  estimated the propensity scores based on the logistic
regression model, using all clinically important variables to esti-
mate the probability of receiving 2 different treatment groups.
Then, we  performed propensity score matching. The propensity
score matching technique [11] used in this study was the nearest-
neighbor matching within speciﬁed calipers [12] using the logic of
the propensity score without replacement with 1-to-1 matching
(1 TRI:1 TFI) using random ordering observation. The value of the
caliper was calculated by multiplying the SD of the mean estimated
propensity score by 0.25 [12].
After matching, we  further tested the balancing of propensity
scores for each covariate between the 2 treatment groups. The esti-
mated mean bias in propensity score was 5.8% and 14.6% in the
propensity score matched sample and in the raw sample (before
matching), respectively. The propensity score matched sample con-
tained 283 subjects each in both treatment groups (TRI vs TFI) with
1:1 allocation. We  ﬁnally estimated the treatment effects [11,13]
on the primary and secondary outcomes of interest using aver-
age treatment effect on the treated (ATT) (TFI effect) and average
treatment effect (ATE) (TFI–TRI).
The National University Hospital Institutional Review Board
approved the study and global consent for the collection of personal
health care information for non-commercial research purposes was
obtained from all subjects upon admission.
Results
From January 2008 to April 2010, 1052 patients underwent pri-
mary PCI within 12 h of STEMI at the National University Heart
Centre. Penetration rate of TRI in our center and distributions of
each operator are shown in Table 1. During this period, the pro-
portion of TRI was  getting higher year by year from 27% in 2008
to 51% in 2010. Of these patients, 359 were selected for TRI and
the remaining 693 patients underwent TFI. Baseline characteristics
of both the TRI and TFI groups are presented in Table 2. Our Asian
patients’ body mass index (BMI) were 24.6 ± 3.4 kg/m2 in the TRI
group, and 24.5 ± 2.5 kg/m2 in the TFI group (p = 0.55). The mean
systolic blood pressure (BP) was  signiﬁcantly higher in patients
with TFI when compared with the TRI group (reference group)
14 T. Kajiya et al. / Journal of Cardiology 62 (2013) 12–17
Table  1





TRI 27% 32% 51%
TFI 73% 68% 49%
B.
Operators
#1  3% 5% 16%
#2  28% 35% 56%
#3  67% 74% 80%
#4 29% 32% 42%
#5 2% 4% 8%
#6  N/A 70% 62%
(A) Distribution of TRI and TFI by years in our center. (B) Percentage of TRI by each
operator. Operator #6 joined our center from 2009.
Table 2
Baseline characteristics of the patients before propensity score matching.
Variables Access site p-Value
TRI (N = 359) TFI (N = 693)
Age 55.8 ± 11.3 57.0 ± 12.1 0.11
Systolic BP 123.6 ± 25.4 135.7 ± 29.8 <0.001
Heart rate 80.5 ± 19.7 80.5 ± 20.0 0.98
Height 166.8 ± 5.8 166.6 ± 5.9 0.52
Weight 68.6 ± 11.2 68.0 ± 8.7 0.37
BMI  24.6 ± 3.4 24.5 ± 2.5 0.55
Gender
Female 46 (12.8%) 107 (15.4%) 0.25
Male 313 (87.2%) 586 (84.6%)
Race
Chinese 201 (56.0%) 366 (52.8%) 0.62
Malays 74 (20.6%) 144 (20.8%)
Indians 57 (15.9%) 116 (16.7%)
Others 27 (7.5%) 67 (9.7%)
Hypertension
No 188 (52.4%) 345 (49.8%) 0.43
Yes  171 (47.6%) 348 (50.2%)
Diabetes
No 254 (70.8%) 475 (68.5%) 0.46
Yes  105 (29.2%) 218 (31.5%)
Previous stroke
No 352 (98.1%) 670 (96.7%) 0.2
Yes  7 (1.9%) 23 (3.3%)
Previous MI
No 332 (92.7%) 632 (91.2%) 0.391
Yes  26 (7.3%) 61 (8.8%)
Previous PCI
No 344 (95.8%) 635 (91.6%) 0.01
Yes  15 (4.2%) 58 (8.4%)
Previous CABG
No 357 (99.4%) 681 (98.3%) 0.16
Yes  2 (0.6%) 12 (1.7%)
CKD
No 357 (99.4%) 669 (96.5%) 0.004
Yes  2 (0.6%) 24 (3.5%)
PAD
No 356 (99.2%) 685 (98.8%) 0.76
Yes  3 (0.8%) 8 (1.2%)
CK-MB
Normal 319 (88.9%) 679 (98.0%) <0.001
Abnormal 40 (11.1%) 14 (2.0%)
AMI  site
Anterior 181(50.4%) 374 (54.0%) 0.27
Non-anterior 178 (49.6%) 319 (46.0%)
Stent type
BMS 258 (71.9%) 471 (68.0%) 0.19
DES  101 (28.1%) 222 (32.0%)
Cardiogenic shock
No 349 (97.2%) 671 (96.8%) 0.73
Yes  10 (2.8%) 22 (3.2%)
GP IIb/IIIa inhibitor
No 113 (31.5%) 441 (63.6%) <0.001
Yes  246 (68.5%) 252 (36.4%)
Table 3
Comparisons of clinical outcomes between TRI and TFI.
Outcomes TRI (N = 359) TFI (N = 693) p-Value
30-Day MACE
(+) 4 (1.1%) 22 (3.2%)
(−) 355 (98.9%) 671 (96.8%) 0.057
Major bleeding
(+) 20 (5.6%) 23 (3.3%)
(−) 339 (94.4%) 670 (96.7%) 0.08
Minor bleeding
(+) 6 (1.7%) 12 (1.7%)
(−) 353 (98.3%) 681 (98.3%) 0.094
Door-to-balloon time > 90 min
(+) 36 (12.4%) 128 (21.4%)
(−) 255 (87.6%) 470 (78.5%) 0.001
(135.7 ± 29.8 mmHg  vs 123.6 ± 25.4 mmHg; p < 0.001). The propor-
tion of patients with a previous history of PCI and presence of
chronic kidney disease (CKD) before the procedure was signiﬁ-
cantly higher in the TFI group when compared with the TRI group.
However, creatine kinase-MB value at admission and the propor-
tion of use of GP IIb/IIIa inhibitor was signiﬁcantly higher in the TRI
group compared with the TFI group. The distribution of age, gender,
race, heart rate, height, weight, BMI, histories of hypertension, dia-
betes, stroke, myocardial infarction, coronary artery bypass graft
(CABG), peripheral artery disease, acute myocardial infarction site,
stent type and presence of cardiogenic shock were similar between
the 2 treatment groups (Table 2).
The unadjusted mean DTB time in the TFI group (72.9 ±
40.2 min) was signiﬁcantly longer compared with the TRI group
(63.6 ± 25.0 min) (p = 0.0003). Unadjusted MACE (1.1% vs 3.2%,
p = 0.057) was  not signiﬁcantly different in both TRI and TFI group
(Table 3). There were 15 deaths, 4 myocardial infarctions, and 3
revascularizations in the TFI group, and 2 deaths, 2 myocardial
infarctions, and 0 revascularizations in the TRI group. Unadjusted
major bleeding (5.6% vs 3.3%, p = 0.08) and minor bleeding (1.7%
vs 1.7%, p = 0.094) were not signiﬁcantly different (Table 3). There
was a twofold greater use of GP IIb/IIIa inhibitor in the TRI
group (68.5%) compared with the TFI group (36.4%) (p < 0.001)
(Table 2).
In the multivariate stepwise logistic regression analysis, heart
rate was  a predictor for 30-day MACE with adjusted OR  of
1.03 (95% CI: 1.01–1.04, p = 0.003) (Table 4). However, no signiﬁcant
difference in 30-day MACE was  seen in the two  groups.
The major bleeding and minor bleeding rates were similar
between the TFI and TRI groups, and being a member of the Malay
population was  a major predictor for major bleeding. Adjusted OR
of the Malay population for development of major bleeding was
3.10 (95% CI: 1.03–9.34, p = 0.044) (Table 4).
Table 4
Adjusted treatment effect of TFI on outcomes: 30-day MACE, major and minor
bleeding.
Outcomes Variables Adjusted odds
ratio
95% CI p-Value
30-Day MACE Heart rate (bpm) 1.03 1.01–1.04 0.003
TFI 2.91 0.99–8.53 0.052
Major bleeding Race (Malay) 3.10 1.03–9.34 0.044
Race (Indian) 1.09 0.22–5.49 0.914
Race (others) 3.08 0.75–12.61 0.117
TFI 1.01 0.37–2.72 0.99
Minor bleeding Race (Malay) 0.35 0.12–1.00 0.051
Race (Indian) 0.68 0.28–1.66 0.392
Race (others) 0.86 0.29–2.51 0.777
TFI 0.59 0.32–1.09 0.09
A multivariate stepwise logistic regression approach was used that included all
baseline characteristics in Table 2.
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Table  5
Adjusted treatment effect estimates for door to balloon time using generalized linear model (GLM).
Variables Adjusted regression coefﬁcient (ˇ) 95% CI p-Value
A.
Age (years) 0.39 0.19–0.58 <0.001
Heart rate (bpm) 0.15 0.03–0.27 0.015
Previous CABG 28.05 4.61–51.49 0.019
TFI  8.58 4.30–12.86 <0.001
Variables Mean door-to-balloon time (min) 95% CI p-Value*
B. Pair-wise comparisons of door to balloon time between signiﬁcant factor variables
Previous CABG (−) 69.5 ± 1.2 66.45–72.61 <0.001
Previous CABG (+) 97.6 ± 11.7 67.01–128.16 <0.001



























CTFI  72.6 ± 1.6 
* Bonferroni adjusted p-values for multiple comparisons.
The GLM using Gaussian family, identity link function and main
ffect model showed that the DTB of TFI group was  8.6 min  longer
han that of TRI group after adjusting for signiﬁcant variables such
s age, heart rate, and previous history of CABG in the model
adjusted regression coefﬁcient (ˇ) for TFI: 8.58, 95% CI: 4.30–12.86,
onferroni adjusted p < 0.001] (Table 5A). The adjusted mean DTB
or the TRI and TFI groups were 64.1 ± 1.5 min  and 72.6 ± 1.6 min,
espectively (Table 5B). The mean DTB time for the group without
 previous history of CABG and the group with a previous his-
ory of CABG were 69.5 ± 1.2 min  and 97.6 ± 11.7 min, respectively
Table 5B).
Propensity score matching identiﬁed 283 matched pairs for DTB
ime, 30-day MACE, and bleeding analysis (Table 6). All the above
ndings were conﬁrmed again by propensity score matched anal-
ses (Table 7). The propensity score matched analyses showed that
he estimated ATT of TFI had a signiﬁcantly longer DTB time when
ompared with their propensity score matched control group (TRI)
69.4 min  in TFI vs 63.6 min  in TRI, p = 0.027) (Table 6). We  did not
ee any signiﬁcant differences in 30-day MACE, major and minor
leeding between the TRI and TFI groups (Table 6).
iscussion
In this single-center observational study investigating differ-
nces in primary outcomes of TRI and TFI for patients with STEMI,
e observed that the TRI group had a shorter DTB time compared
ith the TFI group.
TFI has been considered the gold-standard access site world-
ide because of its long history of use, the wide availability of
everal dedicated catheters that performed well, and the possibility
able 6
ropensity score matched analysis to detect average treatment effect (TRI vs TFI) on outc
Variables TFI TRI 
Door-to-balloon time
Unmatched 72.9 (min) 63.6 (min) 
ATT  69.4 (min) 63.6 (min) 
30-Day MACE
Unmatched 3.0 (%) 1.0 (%) 
ATT  3.0 (%) 1.0 (%) 
Major  bleeding
Unmatched 1.5 (%) 1.0 (%) 
ATT  2.1 (%) 1.1 (%) 
Minor  bleeding
Unmatched 3.7 (%) 5.5 (%) 
ATT  6.0 (%) 5.3 (%) 
Door-to-balloon time > 90 min
Unmatched 21.4 (%) 12.4 (%) 
ATT  17.7 (%) 11.7 (%) 
linical outcomes before and after propensity score matched analysis using 1:1 matching68.49–76.76 <0.001
to exploit relatively large-diameter catheters and sheaths, should
these be necessary for complex PCI. The femoral artery has been the
preferred access site especially for primary PCI. The age of the oper-
ator and long-time expertise with TFI are often cited as reasons
why traditionally trained operators are not keen to choose TRI [14].
Many interventional cardiologists are reluctant to use radial artery
access for primary PCI because of its anatomical character of small
lumen, and therefore a higher risk of spasm, as well as challenging
subclavian and aortic anatomy pathways. It is frequently felt that
the use of the transradial route to restore coronary ﬂow is exces-
sively time consuming in STEMI cases. These had been perceived
as the reasons for the considerable delay in DTB time.
However, our study has shown that DTB time was not prolonged
in the TRI group, which supports the ﬁndings of 3 other studies
[7,15,16]. In our study, multivariate analysis showed that a previous
history of CABG was a major predictor for prolonged DTB time. It
is well known that TRI has a steep learning curve compared with
TFI, and cases of prior CABG should not be selected for TRI unless
the procedure is performed by the most experienced operators [17].
We  have not compared DTB time between groups with and without
a previous history of CABG, but after propensity score matching,
our results showed signiﬁcantly shorter DTB time in the TRI group.
There may  be other factors that affect DTB, which would include
operator’s experience and judgment. Those factors are difﬁcult to
be statistically analyzed.
Because radial artery diameter correlates well with anthro-
pometric measurements, concerns remain over whether radial
access failure and spasm may  occur more frequently in Asians
than in Caucasians. The mean height and weight of our patients
were 166.6 ± 5.8 cm and 68.3 ± 9.6 kg. Maddury et al. reported
omes.
Difference S.E. T-Stat p-Value
9.28 2.57 3.61 0.0003
5.77 2.61 2.21 0.027
2.0 1.0 1.70 0.894
2.0 1.0 1.52 0.129
0.47 0.83 0.57 0.571
1.06 1.05 1.01 0.313
−1.82 1.45 −1.26 0.209
0.7 1.94 0.36 0.714
9.03 2.76 3.27 0.0011
6.01 2.97 2.02 0.043
 without replacement.
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Table  7
Bias reduction diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched sample before and after matching.
Variables TFI TRI % bias % reduction bias p-Value
Age
Unmatched 56.9 55.7 9.9 0.173
Matched 56.9 55.6 10.5 −5.9 0.212
Gender (male)
Unmatched 0.86 0.89 −8.1 0.263
Matched 0.88 0.88 −2.1 73.9 0.796
Racea (Malays)
Unmatched 0.21 0.2 0.7 0.919
Matched 0.24 0.2 7.9 −983 0.363
Racea (Indians)
Unmatched 0.16 0.16 −1.2 0.867
Matched 0.14 0.17 −8.6 −620.6 0.295
Racea (others)
Unmatched 0.1 0.07 9.5 0.196
Matched 0.1 0.07 7.6 20 0.366
Systolic BP
Unmatched 136.1 125.2 39.3 <0.001
Matched 127.9 125.9 7.2 81.5 0.363
Heart  rate
Unmatched 80.4 80.5 −0.6 0.934
Matched 80.4 80.4 −0.1 87.8 0.993
BMI
Unmatched 24.5 24.5 −0.4 0.95
Matched 24.4 24.4 −0.4 18.4 0.965
Previous PCI
Unmatched 0.08 0.03 20.4 0.007
Matched 0.05 0.04 4.5 77.7 0.524
CKD
Unmatched 0.03 0.01 16.4 0.037
Matched 0.01 0.01 5.4 67.2 0.413
Diabetes
Unmatched 0.31 0.29 4.6 0.526
Matched 0.29 0.29 0.8 83 0.926
GP  IIb/IIIa inhibitor use
Unmatched 0.37 0.74 −79.1 <0.001
Matched 0.66 0.73 −16 79.7 0.056
DES
Unmatched 0.32 0.28 7.5 0.298
Matched 0.27 0.29 −3.1 58.8 0.708
Cardiogenic shock
























wMatched 0.03 0.02 
a Race (Chinese) served as a reference group.
hat elective TRI was feasible and safe in Asian females (average
eight, 151.7 ± 8.4 cm;  average weight, 58.1 ± 12.5 kg; average BMI,
5.2 ± 4.6 kg/m2) [18]. However, only 90 patients were included in
his study. In the RIVAL study [19], patients with BMI  > 25 kg/m2
omprised 69.2% of all patients, and in the REAL multicenter reg-
stry [5], the mean BMI  was 27.3 ± 4.3 kg/m2 in the TRI group and
6.8 ± 4.1 kg/m2 in the TFI group. In the HORIZONS-AMI trial [6],
he mean BMI  was 27.3 kg/m2 in the TRI group and 27.1 kg/m2
n the TFI group. In contrast, our study comprises samples whose
ean BMI  was 24.5 ± 2.8 kg/m2. Our Asian patient population had
bviously smaller body size than previous studies as expected.
hrough this study, we found that primary PCI with radial access
s as successful as with femoral access despite the smaller radial
rtery size in Asians. This is consistent with the ﬁndings in other
tudies based on Caucasian and non-Asian populations [1–7]. BMI
tself may  not always represent body size, however a previous study
howed that femoral artery diameter size was correlated with BMI
20].
Approximately 50% of interventional cardiologists think that TRI
ractice will increase in the future especially in the USA, India, and
hina [14]. Meta-analyses have revealed signiﬁcant reductions in
ortality, MACE, major bleeding events, and access site compli-
ations of radial vs femoral PCI [1,2,7]. Arzamendi et al. showed
 fourfold reduction in bleeding and signiﬁcant MACE reduction
ith the radial approach in primary PCI [21]. In our study, there6.6 5 0.433
was a trend that 30-day MACE was  lower in the TRI group, but not
signiﬁcantly (p = 0.129). In the recently reported randomized RIFLE-
STEACS study, TRI was  associated with signiﬁcantly lower rates of
cardiac mortality and bleeding [22], which reﬂects the same trend
as our study.
A perceived beneﬁt of TRI in STEMI is that operators are no
longer constrained in their choice of anti-thrombotic treatment
because of the reduction in access site bleeding with TRI. Nowa-
days we have a variety of choices of antiplatelet agent [23], to select
better agents bleeding complications should be minimized. In our
study, operators used GP IIb/IIIa inhibitors more liberally in TRI
patients compared with TFI patients, likely accounting for the lack
of bleeding reduction that is frequently observed with TRI. This
is in contrast to the results of Arzamendi et al.’s study, in which
TRI was associated with less bleeding despite more frequent GP
IIb/IIIa inhibitor use [21]. We therefore suggest that the use of GP
IIb/IIIa inhibitors be guided by clinical need rather than access site,
as major bleeding frequently occurs in anatomical locations distant
from the access site.
Although we  used propensity score matched analysis, selection
bias for the TRI and TFI groups cannot be completely excluded.
Before matching, there were 15 deaths, 4 myocardial infarctions,
and 3 revascularizations in the TFI group, and 2 deaths, 2 myocar-
dial infarctions, and 0 revascularizations in the TRI group. Despite
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as residual unmeasured bias that cannot be corrected by propen-
ity score matched analysis.
This study has limitations related to study design and meth-
ds of data collections. First, it is a retrospective non-randomized
tudy where all confounding factors and biases could not be elimi-
ated from the picture. There is a possibility of substantial selection
ias with regard to patient selection, as well as the experience and
edication of the operators. However, by performing propensity-
atched analysis, we did minimize the bias considerably (Table 7).
econd, conversion from radial access to femoral access, and vice
ersa, was not systematically captured in this study. Radial access
ailure is higher than femoral access failure in most studies and this
ay  account for the longer DTB with radial access in other studies.
hird, sheath size was not systematically captured in this study.
reater sheath size is associated with increased access site bleed-
ng. The default sheath size for both TRI and TFI in our center is 6F.
n inventory review during the study period showed that 88% of
heaths used were 6F.
In conclusion, TRI was  not associated with longer DTB times than
FI in this single-center propensity-matched analysis of patients
ndergoing primary PCI for STEMI. Our data show that the transi-
ion to TRI in STEMI can be safely achieved with DTB times that are
omparable and possibly better than TFI.
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